Duearity AB (publ) (DEAR.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -26.19 Million SEK | -35.6% |
| 2022 | -19.31 Million SEK | -24.46% |
| 2021 | -15.51 Million SEK | -1071.21% |
| 2020 | -1.32 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.83 Million SEK | 32.76% |
| 2024 Q1 | -7.19 Million SEK | 10.19% |
| 2023 FY | -26.19 Million SEK | -35.6% |
| 2023 Q2 | -6.26 Million SEK | -69.67% |
| 2023 Q1 | -3.69 Million SEK | 11.8% |
| 2023 Q4 | -8.01 Million SEK | 2.72% |
| 2023 Q3 | -8.23 Million SEK | -31.47% |
| 2022 Q4 | -4.18 Million SEK | -4.94% |
| 2022 FY | -19.31 Million SEK | -24.46% |
| 2022 Q1 | -5.62 Million SEK | -20.94% |
| 2022 Q3 | -3.99 Million SEK | 26.52% |
| 2022 Q2 | -5.43 Million SEK | 3.45% |
| 2021 Q3 | -3.93 Million SEK | 6.08% |
| 2021 FY | -15.51 Million SEK | -1071.21% |
| 2021 Q4 | -4.65 Million SEK | -18.05% |
| 2021 Q1 | -2.65 Million SEK | 0.0% |
| 2021 Q2 | -4.19 Million SEK | -57.85% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | -1.32 Million SEK | 0.0% |
| 2020 Q3 | -224 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 66.354% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 125.304% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 125.304% |
| Arcoma AB | 2.56 Million SEK | 1121.451% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 81.074% |
| BICO Group AB (publ) | -835.7 Million SEK | 96.866% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 204.856% |
| CellaVision AB (publ) | 130.3 Million SEK | 120.098% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 67.177% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 10.267% |
| C-Rad AB (publ) | 35.52 Million SEK | 173.714% |
| Dignitana AB (publ) | -17.36 Million SEK | -50.838% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 72.373% |
| Getinge AB (publ) | 2.41 Billion SEK | 101.086% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 61.472% |
| Iconovo AB (publ) | -45.89 Million SEK | 42.934% |
| Integrum AB (publ) | 4.03 Million SEK | 749.477% |
| Luxbright AB (publ) | -25.37 Million SEK | -3.211% |
| Mentice AB (publ) | -2.81 Million SEK | -829.712% |
| OssDsign AB (publ) | -130.49 Million SEK | 79.93% |
| Paxman AB (publ) | 8.33 Million SEK | 414.406% |
| Promimic AB (publ) | -9.22 Million SEK | -183.995% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 83.627% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 52.883% |
| ScandiDos AB (publ) | -14.64 Million SEK | -78.808% |
| Sectra AB (publ) | 428.38 Million SEK | 106.114% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 56.066% |
| Senzime AB (publ) | -134.14 Million SEK | 80.477% |
| SpectraCure AB (publ) | -20.44 Million SEK | -28.125% |
| Stille AB | 26.64 Million SEK | 198.289% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 99.32% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 128.523% |